BG-75202 features among several projects starting first-in-human trials.
ApexOnco Front Page
Recent articles
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
